Search clinical trials for: TG-1101

Total 1376 results

TG Therapeutics, Inc.

Recruiting

Study to Evaluate Efficacy When Transitioning From a Current Disease Modifying Therapy (DMT) to Ublituximab (ENHANCE)

Relapsing Multiple Sclerosis

United States
University of Alabama at Birmingham

Terminated

Clinical Trial of Ublituximab and Umbralisib With CHOP (U2-CHOP) Followed by U2 Maintenance (U2-CHOP-U2) in Previously Untreated Mantle Cell Lymphoma (MCL) (CHOP U2)

Mantle Cell Lymphoma

United States
TG Therapeutics, Inc.

Completed

Ublituximab in Combination With Ibrutinib Versus Ibrutinib Alone in Participants With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) (GENUINE)

Chronic Lymphocytic Leukemia

United States, Israel
TG Therapeutics, Inc.

Terminated

A Study to Evaluate the Safety and Efficacy of Ublituximab in Combination With Umbralisib for Participants Previously Enrolled in Protocol UTX-TGR-304

Chronic Lymphocytic Leukemia

United States, Poland, Italy, United Kingdom
Weill Medical College of Cornell University
TG Therapeutics, Inc.

Terminated

Umbralisib Plus Ublituximab (U2) in Progressive CLL After Novel Therapy

Chronic Lymphocytic Leukemia | CLL/SLL | CLL Progression

United States
TG Therapeutics, Inc.

Completed

Study of TG-1801 in Subjects With B-Cell Lymphoma

B-Cell Lymphoma

Australia
TG Therapeutics, Inc.

Active, not recruiting

Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic Leukemia

Follicular Lymphoma | Marginal Zone Lymphoma | DLBCL | CLL | MCL | Indolent Lymphoma | Richter's Transformation | SLL | Mediastinal Large B-cell Lymphoma | Aggressive Lymphoma

United States
TG Therapeutics, Inc.
Memorial Sloan Kettering Cancer Center

Completed

Study of Immunotherapy in Combination With Ublituximab and Umbralisib in Patients With Relapsed-refractory CLL or Richter's Transformation

Chronic Lymphocytic Leukemia | Richter Syndrome

United States
TG Therapeutics, Inc.

Terminated

Study of TG-1701, an Irreversible Bruton's Tyrosine Kinase Inhibitor, in Patients With B-Cell Malignancies

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

Australia, Poland
TG Therapeutics, Inc.

Completed

Phase IIa Study of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis

Multiple Sclerosis

United States
TG Therapeutics, Inc.

Terminated

Study to Assess Umbralisib Plus Ublituximab in Participants With Treatment Naïve Follicular Lymphoma

Follicular Lymphoma | Small Lymphocytic Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Withdrawn

Tazemetostat in Combination With Umbralisib and Ublituximab for the Treatment Relapsed or Refractory Follicular Lymphoma

Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma

United States
TG Therapeutics, Inc.

Terminated

Study to Assess the Efficacy and Safety of Ublituximab in Combination With Umbralisib and Venetoclax Compared to Ublituximab in Combination With Umbralisib in Subjects With CLL (ULTRA-V) (ULTRA-V)

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
TaiGen Biotechnology Co., Ltd.

Completed

Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections

Diabetic Foot Infections

Taiwan, United States, South Africa, Thailand
Universiteit Antwerpen

Completed

the Effect of a Red Rice Nutrition Supplement on Cholesterol Levels

Cholesterol Level | HDL Level | LDL Level | TG Level

Belgium
Kolon TissueGene, Inc.

Not yet recruiting

Study to Determine the Safety and Tolerability of TG-C in Subjects With Back Pain Due to Degenerative Disc Disease

Degenerative Disc Disease
TG Therapeutics, Inc.

Terminated

Study to Assess the Efficacy and Safety of Ublituximab and Umbralisib in Participants With Chronic Lymphocytic Leukemia (CLL) Currently Treated With Ibrutinib, Acalabrutinib or Venetoclax

Chronic Lymphocytic Leukemia

United States
TG Therapeutics, Inc.

Active, not recruiting

An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis

Relapsing Multiple Sclerosis (RMS)

United States, Belarus, Croatia, Georgia, Poland, Russian Federation, Serbia, Ukraine
TG Therapeutics, Inc.

Terminated

Extension Trial of Ublituximab and TGR-1202 in Combination or as Single Agents in Subjects Currently Receiving Treatment on Ublituximab and/or TGR-1202 Trials

Chronic Lymphocytic Leukemia | Non Hodgkin Lymphoma

United States
City of Hope Medical Center
National Cancer Institute (NCI)

Active, not recruiting

Acalabrutinib, Umbralisib, and Ublituximab for the Treatment of Previously Untreated Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
Fundación Pública Andaluza para la Investigación...
University of Malaga

Unknown

Telematic Program for the Treatment of Depression in Type 1 Diabetes

Depression | Type 1 Diabetes Mellitus

Spain
TG Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 ) (ULTIMATE 1)

Relapsing Multiple Sclerosis (RMS)

United States
TG Therapeutics, Inc.
SCRI Development Innovations, LLC

Completed

Evaluate the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies

Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Chronic Lymphocytic Leukemia | Peripheral T-Cell Lymphoma

United States
TG Therapeutics, Inc.

Terminated

Study to Assess the Efficacy and Safety of Ublituximab + Umbralisib With or Without Bendamustine and Umbralisib Alone in Patients With Previously Treated Non-Hodgkins Lymphoma (UNITY-NHL)

Follicular Lymphoma | Diffuse Large B-Cell Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Small Lymphocytic Lymphoma

United States, Poland, Australia, Italy, United Kingdom, Israel, Korea, Republic of, Slovakia, Spain
Yazeed Sawalha

Withdrawn

Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Refractory Grade 1 Follicular... and other conditions
TG Therapeutics, Inc.
James P. Wilmot Cancer Center

Terminated

Phase I/II Study of Venetoclax or Lenalidomide in Combination With Ublituximab and Umbralisib in Subjects With Relapsed or Refractory CLL/SLL and NHL

Chronic Lymphocytic Leukemia | Non-Hodgkin Lymphoma

United States
TG Therapeutics, Inc.

Terminated

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Non-Hodgkins Lymphoma | Small Lymphocytic Lymphoma | B-cell Lymphomas

United States
TG Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) (ULTIMATE II)

Relapsing Multiple Sclerosis (RMS)

United States
Institute of Bioengineering and Bioimaging (IBB)
National Skin Centre, Singapore

Recruiting

Non-invasive Photoacoustic Imaging of Skin Inflammatory Disorders With Machine Learning-assisted Scoring

Psoriasis | Eczema

Singapore
NeuroBo Pharmaceuticals Inc.

Completed

Efficacy and Safety of Gemcabene in Patients With Low HDL-C and Either Normal or Elevated Triglycerides

Hypercholesterolemia | Hypertriglyceridemia
TG Therapeutics, Inc.

Terminated

Study of Cosibelimab in Subjects With Relapsed or Refractory Lymphoma

B-cell Non Hodgkin Lymphoma | Richter's Transformation

United States
TG Therapeutics, Inc.

Completed

Evaluate the Efficacy and Safety of TGR-1202 in Patients With Chronic Lymphocytic Leukemia Who Are Intolerant to Prior Therapy

Chronic Lymphocytic Leukemia

United States
GPCR Therapeutics, Inc.

Completed

Safety and PK/PD of TG-0054 in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients

Multiple Myeloma | Hodgkin Disease | Non-Hodgkin Lymphoma

Taiwan
Asana BioSciences

Completed

Study to Evaluate ASN008 Topical Gel (TG)

Dermatitis, Atopic | Pruritus | Dermatitis Eczema

United States, Canada
TG Therapeutics, Inc.
SCRI Development Innovations, LLC

Completed

TGR-1202 Alone and in Combination With Either Nab-paclitaxel + Gemcitabine or With FOLFOX in Patients With Select Relapsed or Refractory Solid Tumors

Gastric Cancer | Colorectal Cancer | Pancreatic Cancer | Esophageal Cancer | Rectal Cancer | Gastrointestinal Stromal Tumor (GIST)

United States
TG Therapeutics, Inc.

Completed

Study to Assess the Efficacy and Safety of Umbralisib in Participants With Non-Follicular Indolent Non-Hodgkin's Lymphoma

Waldenstrom Macroglobulinemia | Marginal Zone Lymphoma | Non Follicular Indolent Non-Hodgkin Lymphoma

United States
TG Therapeutics, Inc.

Completed

An Extension of the TG1101-RMS201 Trial

Relapsing Remitting Multiple Sclerosis

United States
TG Therapeutics, Inc.

Completed

TGR-1202, a PI3K Delta Inhibitor, in Combination With Obinutuzumab and Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)

Chronic Lymphocytic Leukemia

United States
TG Therapeutics, Inc.

Not yet recruiting

A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS) (ENABLE)

Multiple Sclerosis | Relapsing Multiple Sclerosis
Shanghai HEP Pharmaceutical Co., Ltd.

Withdrawn

A Study to Access the Efficacy in Type 2 Diabetes Mellitus on Stable Metformin

Type 2 Diabetes Patients
Jamia Hamdard University

Completed

Clinical Study to Evaluate Antihyperlipidemic Effect of a Classical Unani Antiobesity Formulation

Hyperlipidemia

India
University of Aarhus
The Novo Nordic Foundation; The Danish Medical Research Council; The Danish Diabetes...

Completed

VLDL-triglyceride Kinetics in Type 2 Diabetes

Type 2 Diabetes

Denmark
TG Therapeutics, Inc.

Terminated

Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia (UNITY-CLL)

Chronic Lymphocytic Leukemia

United States, Israel, Italy, Poland, Russian Federation, Spain, United Kingdom
TG Therapeutics, Inc.

Completed

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

B-cell Lymphoma | Marginal Zone Lymphoma | Primary Central Nervous System Lymphoma | Waldenstrom's Macroglobulinemia | Non-Hodgkins Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
TG Therapeutics, Inc.

Completed

Ublituximab + Ibrutinib in Select B-cell Malignancies

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia

United States
TG Therapeutics, Inc.

Completed

Novel PI3K Delta Inhibitor TGR-1202, in Combination With Brentuximab Vedotin for Hodgkin's Lymphoma Patients

Hodgkin's Lymphoma

United States
GPCR Therapeutics, Inc.

Completed

PD and Safety of TG-0054 Combined With G-CSF in Multiple Myeloma, Non-Hodgkin Lymphoma and Hodgkin Disease Patients

Multiple Myeloma | Hodgkin Disease | Non-Hodgkin Lymphoma

United States
Vejle Hospital
Aarhus University Hospital; Danish Cancer Society; Centre for Oncology Education...

Active, not recruiting

Reducing Fear of Cancer Recurrence in Danish Colorectal Cancer Survivors

Colorectal Cancer | Anxiety | Health Anxiety | Bodily Distress Syndrome | Fear of Cancer Recurrence

Denmark
TaiGen Biotechnology Co., Ltd.
R&G Pharma Studies Co.,Ltd.

Completed

To Evaluate the Safety, Tolerability, and Pharmacokinetics Profiles of TG-1000 in Healthy Volunteers, and the Food Effect on Pharmacokinetics of Single Oral Dose of TG-1000 in Healthy Volunteers.

Healthy Chinese Volunteers

China
TaiGen Biotechnology Co., Ltd.

Completed

A Study to Evaluate the Safety, Tolerability, and PK in Healthy Volunteers and HCV Genotype 1 Infected Patients

Healthy | Hepatitis C, Chronic

United States

Search clinical trials for: TG-1101

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Togo

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations